Details of the Drug

General Information of Drug (ID: DMH0LM2)

Drug Name
POT-4
Synonyms AL-78898A; POT-4 EOS Insert; Compstatin complement-inhibiting peptides, Pennsylvania/Potentia; 4(1MeW)7W
Indication
Disease Entry ICD 11 Status REF
Macular degeneration 9B78.3 Phase 2 [1]
Structure 3D Structure is Not Available
3D MOL 2D MOL
Cross-matching ID
TTD ID
D01SQI

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C3 (CO3) TTJGY7A CO3_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01157065) Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration. U.S. National Institutes of Health.
2 Compstatin: A Complement Inhibitor on its Way to Clinical Application. Adv Exp Med Biol. 2008; 632: 273-292.
3 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
4 National Cancer Institute Drug Dictionary (drug id 599816).
5 The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Jun;215:108450.
6 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7 Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
8 Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22.